|Jay T. Flatley|
Chief Executive Officer
Jay was appointed President and CEO of Illumina in 1999, and has taken the company from $1.3 million in sales in 2000 to over $1.8 billion in 2014, representing a compound annual growth rate in excess of 90%. He oversaw the company's expansion into the whole genome sequencing area with the acquisition of Solexa in 2006, and more recently into diagnostics and consumer sequencing. Under his leadership, Illumina has been named multiple times to the Deloitte & Touche Fast 50 and Fast 500 lists, as well as to the Forbes 25 Fastest-Growing Tech Companies (2007, 2009 and 2010), the Fortune 100 Fastest-Growing Companies (2010 and 2011) lists, and recognition by MIT Technology Review as the World's Smartest Company in 2014.
Previously, Jay served as President and Chief Executive Officer of Molecular Dynamics, later acquired by Amersham Pharmacia Biotech and now a part of GE Healthcare. As a co-founder and member of the board of directors for Molecular Dynamics he led the company to its initial public offering in 1993. While there, he also helped Molecular Dynamics develop and launch over 15 major instrumentation systems, including the first capillary-based DNA sequencer. Prior to joining Molecular Dynamics, Jay was Vice President of Engineering and Strategic Planning for Plexus Computers, Executive Vice President for Manning Technologies and held various positions at Spectra Physics. Currently, he is an Advisory Board member for UC San Diego's Moore Cancer Center, and a member of the Board of Directors at Coherent, Denali, and Illumina, Inc.